Evidence map›Paper›PMID 29849092›Full record

ArticleScientific reports2018

Hetero-Multivalency of Pseudomonas aeruginosa Lectin LecA Binding to Model Membranes.

Nolan C Worstell, Akshi Singla, Panatda Saenkham, Thushara Galbadage, Preeti Sule, Dongheon Lee, Alec Mohr, Joseph Sang-Il Kwon, Jeffrey D Cirillo, Hung-Jen Wu

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Role of cell-associated and secretion-independent virulence factors of Pseudomonas aeruginosa in microbial keratitis and anti-virulence therapeutic strategies.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Assessment of the Glycan-Binding Profile ofbioRxiv : the preprint server for biology · 2023
    Article
  12. Hetero-Multivalent Targeted Liposomal Drug Delivery to TreatACS applied materials & interfaces · 2022
    Article
  13. Article
  14. Article
  15. Article
  16. Tandem sialoglycan-binding modules in aThe Journal of biological chemistry · 2020
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Nolan C WorstellDepartment of Chemical Engineering, Texas A&M University, College Station, Texas, USA.
Akshi SinglaDepartment of Chemical Engineering, Texas A&M University, College Station, Texas, USA.
Panatda SaenkhamDepartment of Microbial Pathogenesis and Immunology, Texas A&M Health Science Center, Bryan, Texas, USA.
Thushara GalbadageDepartment of Microbial Pathogenesis and Immunology, Texas A&M Health Science Center, Bryan, Texas, USA.
Preeti SuleDepartment of Microbial Pathogenesis and Immunology, Texas A&M Health Science Center, Bryan, Texas, USA.
Dongheon LeeDepartment of Chemical Engineering, Texas A&M University, College Station, Texas, USA.ORCID 0000-0002-4066-9222
Alec MohrDepartment of Chemical Engineering, Texas A&M University, College Station, Texas, USA.
Joseph Sang-Il KwonDepartment of Chemical Engineering, Texas A&M University, College Station, Texas, USA.
Jeffrey D CirilloDepartment of Microbial Pathogenesis and Immunology, Texas A&M Health Science Center, Bryan, Texas, USA.
Hung-Jen WuDepartment of Chemical Engineering, Texas A&M University, College Station, Texas, USA. hjwu@tamu.edu.ORCID 0000-0003-3082-7431
Texas A&M University · USTexas A&M Health Science Center · US

Funding

Microvesicle Isolation from Mycobacterium tuberculosis infected macrophage usingR03AI113585 · NIAID · TEXAS ENGINEERING EXPERIMENT STATION · PI UGAZ, VICTOR M, WU, HUNG-JEN · 2014 to 2015
$137k
NIAID NIH HHS R03 AI113585
6 · The paper itself

Abstract

A single glycan-lectin interaction is often weak and semi-specific. Multiple binding domains in a single lectin can bind with multiple glycan molecules simultaneously, making it difficult for the classic "lock-and-key" model to explain these interactions. We demonstrated that hetero-multivalency, a homo-oligomeric protein simultaneously binding to at least two types of ligands, influences LecA (a Pseudomonas aeruginosa adhesin)-glycolipid recognition. We also observed enhanced binding between P. aeruginosa and mixed glycolipid liposomes. Interestingly, strong ligands could activate weaker binding ligands leading to higher LecA binding capacity. This hetero-multivalency is probably mediated via a simple mechanism, Reduction of Dimensionality (RD). To understand the influence of RD, we also modeled LecA's two-step binding process with membranes using a kinetic Monte Carlo simulation. The simulation identified the frequency of low-affinity ligand encounters with bound LecA and the bound LecA's retention of the low-affinity ligand as essential parameters for triggering hetero-multivalent binding, agreeing with experimental observations. The hetero-multivalency can alter lectin binding properties, including avidities, capacities, and kinetics, and therefore, it likely occurs in various multivalent binding systems. Using hetero-multivalency concept, we also offered a new strategy to design high-affinity drug carriers for targeted drug delivery.

Indexed as

Pseudomonas aeruginosaAdhesins, BacterialKineticsLigandsLiposomesMonte Carlo MethodProtein BindingAdhesins, BacterialLecA protein, bacteriaLigandsLiposomes

Identifiers

PMID29849092
PMCPMC5976636
OpenAlexW2807492226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.